<DOC>
	<DOCNO>NCT01074008</DOCNO>
	<brief_summary>This study assess safety , tolerability , pharmacokinetics , antiviral activity multiple oral dos ABT-450/ritonavir ( r ) , ABT-333 ( also know dasabuvir ) , ABT-072 hepatitis C virus ( HCV ) , genotype 1-infected , treatment-naïve adult .</brief_summary>
	<brief_title>A Randomized Study Evaluate Safety , Tolerability Antiviral Activity ABT-450 , ABT-333 ABT-072</brief_title>
	<detailed_description>This Phase 2a , randomize , blind , placebo-controlled , dose-ranging study chronically , hepatitis C virus ( HCV ) genotype 1-infected participant design explore safety , tolerability , pharmacokinetics , antiviral activity , well evolution persistence resistance ABT-450/r , ABT-333 , ABT-072 . Participants treat ABT-450/r , ABT-333 , ABT-072 monotherapy 3 day , follow 81 day ( 12 week minus 3 day monotherapy ) ABT-450/r , ABT-333 , ABT-072 combine pegylated interferon/ribavirin ( pegIFN/RBV ) , follow 36 week pegIFN/RBV alone . Participants randomize ABT-450/r treatment group achieve rapid virologic response ( RVR ) HCV ribonucleic acid ( RNA ) level &lt; 25 IU/mL subsequent visit eligible stop pegIFN/RBV therapy Week 24 .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Antiviral Agents</mesh_term>
	<criteria>Chronic hepatitis C virus ( HCV ) , genotype 1 infection ( HCV ribonucleic acid level great equal 100,000 IU/mL ) screen Liver biopsy within 3 year histology consistent HCVinduced liver damage , evidence cirrhosis liver pathology due cause chronic HCV Treatment naïve male female age 18 65 Females must postmenopausal 2 year surgically sterile Negative screen drug alcohol Negative hepatitis B surface antigen ( HBsAg ) antihuman immunodeficiency virus antibody ( antiHIV Ab ) No use cytochrome P450 3A ( CYP3A ) cytochrome P450 2C8 ( CYP2C8 ) enzyme inducer inhibitor within 1 month dose Be condition general good health , perceive investigator , HCV infection Significant sensitivity drug Use herbal supplement within 2 week prior study drug dose History major depression within 2 year Prior treatment investigational commercially available antiHCV agent Abnormal laboratory test</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2014</verification_date>
</DOC>